Creatine Monohydrate: What Does the ISSN Position Stand Actually Conclude?

The short answer#

The 2017 International Society of Sports Nutrition (ISSN) position stand reaches a confident verdict on exactly one thing: creatine monohydrate is the most effective researched nutritional supplement for raising high-intensity exercise capacity and building lean body mass during training, and it carries a strong safety record at the doses studied. Everything the document says about clinical and neuroprotective uses is written far more cautiously. The most useful way to read the paper is to watch for the exact sentence where the confident language runs out and the hedged language starts, because that boundary marks a real difference in the quality of the evidence.

Key points#

• The ISSN stand is emphatic about performance and lean mass, and honest that the benefit is concentrated in short, intense, repeated efforts rather than steady endurance work.
• It reports no compelling evidence of harm in healthy people at intakes up to 30 grams per day over several years.
• A rise in serum creatinine after supplementation usually reflects more creatinine being produced, not failing kidneys.
• Claims about recovery, rehabilitation, and neuroprotection are framed as areas needing further research, not settled treatments.
• Safety data describe healthy, studied populations, so pregnancy, kidney disease, or other medications are individual conversations with a clinician.

Why the source format matters before you read a word#

A position stand is not a single trial. It is a professional society's structured synthesis of a large literature, assembled by a panel to represent a consensus reading. That format buys breadth and costs resolution. The breadth is real: the creatine document draws on decades of work across hundreds of studies. The cost is that a consensus summary blends findings of very different weight, so a single confident sentence can sit on top of dozens of randomized trials in one place and a handful of small pilot studies in another.

A helpful way to picture it is a topographic map printed at low resolution. It shows you the terrain, but the smoothed contour lines hide whether a slope is a gentle rise or a cliff. Reading a position stand well means restoring that resolution yourself, asking of each conclusion what actually sits underneath it. In the creatine paper, some statements rest on an unusually deep and consistent body of trials. Others are labeled as warranting further study, which is the courteous scientific way of saying interesting but unproven.

Where the evidence is deep: performance and lean mass#

Here the literature is broad and the stand says so without hedging. Its headline conclusion is that creatine monohydrate is the most effective ergogenic nutritional supplement available to athletes aiming to increase high-intensity capacity and lean body mass during training. The mechanism is well characterized. Supplementation raises the phosphocreatine stored in muscle, which speeds the regeneration of adenosine triphosphate during short, hard efforts. More available energy for repeated bouts allows more work per session, and more work accumulated over weeks tends to produce larger training adaptations.

Two honest qualifiers keep this from being a blanket promise. First, the payoff is concentrated in short-duration, high-intensity, repeated-effort work such as sprints and resistance training, and it does little for steady endurance activity. Second, the fast lean-mass jump in the first days is partly water pulled into muscle, layered on top of genuine training-driven protein gains that accrue over longer periods. The direction of the effect is settled across many controlled studies. The size of it varies with the individual, with diet, and with baseline muscle creatine, which is why people who start with lower stores, such as those eating little or no meat, often respond more.

The safety record, and the creatinine trap#

The safety conclusion is grounded in the same way. The stand reports no compelling scientific evidence that short- or long-term creatine monohydrate use, at intakes up to 30 grams per day for as long as five years, causes harm in healthy people. It notes that clinical groups have received high doses, on the order of 0.3 to 0.8 grams per kilogram per day, over extended periods without serious adverse events being attributed to the supplement.

The single most practical thing the document clears up is a recurring misread of a lab value. The body converts creatine into creatinine, and serum creatinine is the number clinicians use to estimate kidney function. Supplementation can push that marker up simply because more creatinine is being generated, not because the kidney has stopped clearing it. The stand states plainly that there is no compelling evidence creatine harms renal function in healthy individuals. That sentence is a statement about a studied population, not a universal all-clear. Someone with existing kidney disease, someone who is pregnant, or someone taking other medications falls outside the groups these data describe, and that belongs in a conversation with a treating clinician rather than a decision made off a supplement label.

Where the evidence thins: clinical and neuroprotective uses#

This is the section where careful reading earns its keep. The same document that speaks firmly about performance shifts into conditional grammar the moment it turns toward medicine. It raises possible roles for creatine in recovery, injury prevention, thermoregulation, rehabilitation, and neuroprotection after concussion or spinal cord injury, and it gestures toward metabolic and neurodegenerative conditions. Each of these is framed as an area that warrants further research rather than an established therapeutic use.

The underlying data explain the change in tone. The neuroprotection signal is strongest in animal models of traumatic brain injury and much thinner in human neurodegenerative disease. Large trials in Parkinson's disease, for instance, have not delivered the benefit that early mechanistic reasoning predicted. So the fair way to read the clinical section is as a catalog of plausible directions supported by preliminary work, not a list of treatments a reader should expect to work. A promising result in a preclinical model is a reason to run a proper trial, not a reason to behave as if the trial already succeeded.

Reading any society document the same way#

The creatine stand doubles as a worked example for reading any consensus document you pick up. Match the strength of each claim to the strength of the evidence beneath it. For high-intensity performance, for lean mass, and for baseline safety at studied doses, the literature is broad and consistent, and the paper says so in plain, confident language. For clinical and neuroprotective applications, the paper deliberately softens its wording, and a careful reader should soften expectations to match. When a single document uses firm language for one claim and hedged language for another, that contrast is not stylistic. It is usually the honest imprint of a real gap in the underlying evidence.